Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Cempra Using Unyvero Diagnostic

By Drug Discovery Trends Editor | August 13, 2012

Curetis AG and Cempra Inc. announced a research and development collaboration to incorporate Curetis’ Unyvero molecular diagnostic system into Cempra’s upcoming global Phase 3 trial of the oral formulation of solithromycin in patients with community-acquired bacterial pneumonia (CABP).

Under the terms of the agreement, each party may use the generated data for its own product development and for its regulatory filings.

Cempra’s randomized, double-blind Phase 3 trial comparing solithromycin against a comparator drug is expected to enroll over 800 patients in more than 100 clinical sites worldwide. Sputum samples from patients will be sent to Curetis for analysis with its Unyvero Solution and the CE-marked Unyvero P50 Pneumonia Application Cartridge. Molecular diagnostic data generated from the Unyvero Solution will be paired with clinical and traditional microbiology data to enhance the pathogen diagnosis rate in the trial. The trial is expected to start during the fourth quarter of 2012 and enrollment is expected to be completed in 2014.

“The collaboration with Cempra, which is developing much-needed novel antibiotics to overcome the resistance problem, is a perfect strategic fit for us,” said Oliver Schacht, PhD, chief executive officer of Curetis AG. “The trial should provide us with an excellent opportunity to generate further data on the clinical sensitivity and specificity of our Unyvero solution in a commercially important indication, which is not yet included in the EU label, nor the one we are currently seeking in the U.S. Moreover, we hope to demonstrate the benefit of the Unyvero solution in an ambulant setting and also generate additional data from frozen samples.”

David Oldach, MD, senior vice president of clinical research of Cempra said, “Improving diagnostic accuracy for the detection of pathogens causing pneumonia is critical to improving the management of these patients. Curetis’ Unyvero assay will enhance the trial’s pathogen and resistance gene detection significantly, and positions our joint effort at the cutting edge of translational clinical science.”

Prabhavathi Fernandes, PhD, president and chief executive officer of Cempra added, “We believe that rapid and accurate identification of infectious pathogens will enable the better selection of appropriate antibiotic therapy and reduce the overuse of antibiotics.”

Date: August 9, 2012
Source: Curetis AG


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50